Who is sponsoring NCT04288622?

NCT04288622 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT04288622?

Interventions in NCT04288622: Weekly standardised, personalised feedback.

What condition does NCT04288622 study?

NCT04288622 studies Women at Risk of Common Mental Disorders.

Is NCT04288622 still recruiting?

NCT04288622 is currently completed. Last updated 24 May 2022.

Last reviewed 2022-05-24 · How we verify

NCT04288622

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ESM-derived Personalised Feedback for Women at Risk of Common Mental Disorder

Completed NA Last updated 24 May 2022

What this trial tests

NA trial testing Weekly standardised, personalised feedback in Women at Risk of Common Mental Disorders in 124 participants. Completed in 31 December 2021.

Timeline

1 March 2020

Primary endpoint
30 August 2021

31 December 2021

Quick facts

Lead sponsor	The University of Hong Kong
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	124
Start date	1 March 2020
Primary completion	30 August 2021
Estimated completion	31 December 2021
Sites	1 location across Hong Kong

Drugs / interventions tested

Weekly standardised, personalised feedback

Conditions studied

Women at Risk of Common Mental Disorders — all drugs for Women at Risk of Common Mental Disorders →

Sponsor

The University of Hong Kong

Who can join

Adults 18 to 64, female only, with Women at Risk of Common Mental Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to examine the effectiveness of Experience Sampling Method (ESM) derived personalised feedback for women at risk of common mental disorder in Hong Kong, in reducing individuals depressive and anxiety symptoms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04288622 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 24 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04288622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing